Multiple Sclerosis
Below is a sample of existing clinical evidence:
“Among the eight cases, six showed therapeutic improvement after hUC-MSCs treatment, and in all eight patients, relapse frequencies decreased to 36.4% of those before the treatment… MRI characteristics also showed decreased volume and severity of lesions, with few adverse events… hUC-MSCs can alleviate disability and reduce relapse of secondary progressive multiple sclerosis by modulating immune responses, which also had been proved to be safe in MS patients.”
– “Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Secondary Progressive Multiple Sclerosis,” Lu et al, Stem Cell Research & Therapy, 2013